These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36380976)

  • 41. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19: Progress in diagnostics, therapy and vaccination.
    Liu X; Liu C; Liu G; Luo W; Xia N
    Theranostics; 2020; 10(17):7821-7835. PubMed ID: 32685022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.
    Ao D; He X; Liu J; Xu L
    Signal Transduct Target Ther; 2023 Dec; 8(1):466. PubMed ID: 38129394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 Vaccines: Status Report.
    Amanat F; Krammer F
    Immunity; 2020 Apr; 52(4):583-589. PubMed ID: 32259480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An overview of COVID-19.
    Shi Y; Wang G; Cai XP; Deng JW; Zheng L; Zhu HH; Zheng M; Yang B; Chen Z
    J Zhejiang Univ Sci B; 2020 May; 21(5):343-360. PubMed ID: 32425000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Third Wave of the COVID-19 Pandemic: Prominence of Initial Public Health Interference.
    Mukherjee S; Ray SK
    Infect Disord Drug Targets; 2022; 22(4):e080222200919. PubMed ID: 35135456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune-mediated approaches against COVID-19.
    Florindo HF; Kleiner R; Vaskovich-Koubi D; Acúrcio RC; Carreira B; Yeini E; Tiram G; Liubomirski Y; Satchi-Fainaro R
    Nat Nanotechnol; 2020 Aug; 15(8):630-645. PubMed ID: 32661375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of virus-like particles-based vaccines against coronaviruses.
    Yong CY; Liew WPP; Ong HK; Poh CL
    Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).
    Ahn DG; Shin HJ; Kim MH; Lee S; Kim HS; Myoung J; Kim BT; Kim SJ
    J Microbiol Biotechnol; 2020 Mar; 30(3):313-324. PubMed ID: 32238757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drugs for COVID-19: An Update.
    Ceramella J; Iacopetta D; Sinicropi MS; Andreu I; Mariconda A; Saturnino C; Giuzio F; Longo P; Aquaro S; Catalano A
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
    Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M
    Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar T; Raut D; Bhatt LK
    Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
    Bostanghadiri N; Ziaeefar P; Mofrad MG; Yousefzadeh P; Hashemi A; Darban-Sarokhalil D
    Biomed Res Int; 2023; 2023():1879554. PubMed ID: 37674935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapeutic approaches to curtail COVID-19.
    Owji H; Negahdaripour M; Hajighahramani N
    Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.